Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
Quick Takeaways: Why It Matters? Piclidenoson’s Phase 2 enrollment milestone, fully funded by Vetbiolix, moves this A3 adenosine receptor agonist closer to potential registration as a chronic oral osteoarthritis option in dogs, with LOAD, VAS, and ...
